The short version of redox activity fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-23. Anything still debated is marked as such rather than presented as settled.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper-binding tripeptide complex | Includes Gly-His-Lys and Cu(II) |
| Molecular formula | C14H22CuN6O4 | Reported for the 1:1 complex |
| Appearance | Blue to blue-violet solid | Color arises from copper d-d transitions |
| Solubility class | Water-soluble; slightly soluble in polar organic solvents | Often prepared as aqueous stock |
| Typical storage | -20 °C, desiccated, protected from light | Limits oxidation and moisture uptake |
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
Solid GHK-Cu appears as a blue to blue-violet powder, and the colour is a direct consequence of copper coordination. The complex dissolves readily in water and in many polar solvents, while the free peptide behaves differently. Solubility in nonpolar media is low, which limits its use in oil-based systems. Solutions are typically prepared fresh because the dissolved form is more exposed to hydrolysis and to loss of the metal ion than the dry powder. Working concentrations are usually low, and preparation notes often specify the solvent and the order of addition.
Dry material is typically held at low temperature, often around minus twenty degrees Celsius, and protected from moisture and light. Copper complexes can release their metal ion under acidic conditions or in the presence of competing chelators. Hydrolysis of the peptide backbone is a slower but real pathway, and the histidine residue is susceptible to oxidation over long periods. Stability statements therefore depend on formulation, pH, and container, and they should be read as conditional rather than absolute.
Copper takes part in redox chemistry, and the same property that makes it useful in enzymes can generate reactive oxygen species when the ion is loosely bound. GHK chelates copper through imidazole, amino, and amide nitrogen donors, which reduces the amount of free copper in solution. Whether that chelation is protective, neutral, or harmful in a given tissue is not settled. Laboratory assays report both antioxidant and pro-oxidant behavior, depending on the conditions and the readout used.
Published work on GHK-Cu is dominated by in vitro experiments and small animal studies. Human trials tend to be short and small, with endpoints such as skin appearance rather than clinical outcomes. Review articles often summarize the same underlying laboratory findings, which can make the evidence base look broader than it is. Several basic questions remain open: the concentration of the intact complex in human tissue, the route by which it crosses the skin barrier, and whether effects seen in culture produce measurable changes in people.
Laboratory studies describe GHK-Cu as a source of copper that cells can take up, with reported effects on collagen, elastin, and glycosaminoglycan synthesis in cultured fibroblasts. The peptide also appears in wound-repair research, where it is linked to the activity of matrix metalloproteinases and their inhibitors. These observations come largely from cell and animal models. How directly the complex controls any single pathway in intact human skin remains an open question, and reported effects depend on concentration, vehicle, and exposure time.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence found naturally in human plasma, saliva and urine. Loren Pickart reported the isolation of the free peptide in 1973 while studying factors that influenced the growth of aged liver cells in culture. The peptide was later shown to bind copper(II) with high affinity, and the metal-bound form became the focus of most subsequent research. Its concentration in circulation declines markedly with age, a pattern that is well documented, though the physiological consequences of that decline remain debated.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
Um 1900 fuhren auf den öffentlichen Straßen fast ebenso viele Dampfwagen (Erfinder: Joseph Cugnot, 1769), Elektroautos (Erfinder: Gustave Trouvé, 1881) und Autos mit Verbrennungsmotor. Der Siegeszug der Autos mit Verbrennungsmotor begann allerdings erst mit der Erfindung des Anlassers und der Einführung der Fließbandproduktion im Jahre 1908 durch Henry Ford. Der St. Pauli-Elbtunnel oder auch alte Elbtunnel in Hamburg wurde am 7. September 1911 zunächst für den Fußgängerverkehr und ab 30. November 1911 auch für Pferdefuhrwerke und Kraftfahrzeuge eröffnet. Der alte Elbtunnel galt bei seiner Eröffnung als technische Sensation. Er unterquert die Norderelbe auf einer Länge von 426,5 Metern und verbindet dabei mit zwei Tunnelröhren die nördliche Hafenkante bei den St. Pauli-Landungsbrücken mit der Elbinsel Steinwerder. Eng verbunden mit der Entwicklung des Automobils ist auch die Geschichte des Führerscheins. Am 1. August 1888 erhielt der Erfinder des Automobils Carl Benz vom Großherzoglich-Badischen Bezirksamt die erste bekannte Fahrerlaubnis in Form einer nur für Mannheim und Umgebung gültigen Berechtigung zur Durchführung von Versuchsfahrten mit einem Patentmotorwagen. Ein für das gesamte Deutsche Reich gültiger Führerschein wurde erstmals am 3. Mai 1909 eingeführt. Die erste private Fahrschule wurde 1904 von Rudolf Kempf in Aschaffenburg eröffnet. Zum 1. Oktober 1907 wurden im Deutschen Reich einheitlich angebrachte Kraftfahrzeugkennzeichen eingeführt.
1899 begannen die Brüder Wright in den USA mit dem Bau ihres ersten Flugapparates, einem Drachen. Er besaß bereits ein äußerst wichtiges Merkmal: die Verwindung der Tragflächen, mit der die waagerechte Lage des Flugapparates kontrolliert werden konnte. Edmund Rumpler sagte zu dieser Erfindung, „welche direkt dem Vogelflug nachgebildet ist“, sie habe „hauptsächlich dazu beigetragen, die großen Erfolge der Brüder Wright herbeizuführen“. Die Nachricht vom Absturz Otto Lilienthals bewog die Gebrüder Wright, eigenen Aussagen zufolge, dazu, sich intensiv mit dem Menschenflug zu beschäftigen. Sie gingen dabei systematisch vor und begannen noch im Jahr 1896 mit dem Studium aller verfügbaren flugtechnischen Literatur. Sie erkannten, dass Lilienthal das Problem des dynamischen Auftriebs gelöst hatte und sein Absturz Folge der mangelhaften Steuerfähigkeit seines Flugapparats gewesen war. Im Oktober 1900 erprobten die Brüder Wright mit einem Doppeldecker-Gleitflugzeug zunächst noch unbemannt den Gleitflug auf den Kill Devil Hills sechs Kilometer südlich von Kitty Hawk in North Carolina. Der Ort auf den Outer Banks an der Atlantikküste eignete sich wegen der dort auftretenden starken und konstanten Winde für dieses Vorhaben besonders.
Als weltweit erstes Flugzeug wurde 1902 der Wright Glider, ein Experimental-Gleitflugzeug, um alle drei Raumachsen (Längs-, Quer- und Gierachse) aerodynamisch gesteuert. Die zur Steuerung benötigten Kräfte wurden durch Umlenkung der umströmenden Luft mit beweglichen Steuerflächen bzw. Tragflächenverwindung erzeugt. Die neue aerodynamische Flugsteuerung wurde 1906 patentiert und ist seitdem das am häufigsten im Flugzeugbau verwendete Verfahren. Der Wright Flyer – die Wright-Brüder selbst benannten das Flugzeug The Whopper Flying Machine (dt. „Die Riesenflugmaschine“) – war das erste von den Brüdern Wright hergestellte Motorflugzeug. Beim weitesten Flug legte es am 17. Dezember 1903 in Kitty Hawk in 59 Sekunden rund 260 Meter zurück. Es war das erste motorisierte Luftfahrzeug, das schwerer als Luft war und von einem Piloten gesteuert wurde. Am 4. Dezember 1894 unternahm der deutsche Meteorologe Arthur Berson eine Alleinfahrt mit dem Wasserstoffballon Phönix und konnte dabei mit einer Höhe von 9155 m ü. NN einen neuen Höhenweltrekord aufstellen. Im Jahr 1900 kam es zu drei Aufstiegen des Zeppelins LZ 1 über dem Bodensee. Die ermutigenden Resultate führten zu einer spontanen Begeisterung in der Bevölkerung, was entscheidend dazu beitrug, dass der Konstrukteur des Luftschiffes Graf von Zeppelin die Technik weiterentwickelte. Am 7. Januar 1901 verlieh der deutsche Kaiser ihm den preußischen Roten Adlerorden I. Klasse für seine Verdienste. 1908 wurde der Deutsche Luftflotten-Verein gegründet, oberstes Vereinsziel war die „Schaffung einer starken deutschen Luftflotte“.
Die Gründung des Vereins ging vor allem auf die Initiative des Mannheimer Industriellen Karl Lanz zurück, der auch Vorsitzender des Luftflotten-Vereins war. Mit dem Lanz-Preis der Lüfte wurde zudem ein Preis in Höhe von 40.000 Reichsmark für technische Innovationen auf dem Gebiet des Flugwesens ins Leben gerufen.
Sources: de.wikipedia.org
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide binds copper through its histidine residue and neighboring amide nitrogens, forming a stable coordination compound. It is studied as a research chemical and used in some cosmetic formulations.
Yes, the peptide and its copper complex have been detected in human plasma, saliva, and urine. Endogenous concentrations are low, and reported levels change with age and physiological state. The biological significance of those changes is still an active area of study.
GHK refers to the free tripeptide without a bound copper ion. GHK-Cu contains copper(II) coordinated to the same peptide backbone. The presence of copper affects the complex's color, stability, and interaction with biological molecules.
The letters GHK are the one-letter codes for glycine, histidine and lysine, the three amino acids in the peptide. The suffix Cu indicates that the peptide is bound to a copper ion, normally copper(II).